Sreenivasa Basavanthappa, MD
Retina Specialist · Bloomington, ILNPI 1497953871
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,149 of the $4,649 with a category attached, or 67.7%. 21 manufacturers reported payments, led by Thrombogenics, Inc. at 32.3% of the total. Reporting peaked in 2019 at $1,959 and has fallen 70.9% since, to $570 in 2025.
Across 118 payments — averaging $39.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Thrombogenics, Inc.$2K
- AbbVie$622
- Regeneron Healthcare Solutions, Inc.$571
- Astellas Pharma US Inc$451
- Genentech USA, Inc.$403
- Apellis Pharmaceuticals, Inc.$240
- plus $861 from 15 others
What the payments were for
- Consulting fees$1,50032%
- Food & beverage$3,14968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Thrombogenics, Inc. | 1 | $1,500 |
| AbbVie(2 entities) | 35 | $622 |
| Regeneron Healthcare Solutions, Inc. | 19 | $571 |
| Astellas Pharma US Inc | 15 | $451 |
| Genentech USA, Inc. | 14 | $403 |
| Apellis Pharmaceuticals, Inc. | 9 | $240 |
| Carl Zeiss Meditec, Inc. | 2 | $229 |
| Biogen | 7 | $156 |
| Hoffmann-la Roche Limited | 1 | $140 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Carl Zeiss Meditec USA, Inc. | 1 | $58 |
| Novartis | 2 | $38 |
| Coherus Oncology, Inc. | 1 | $28 |
| Genentech, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Alcon | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
| Alimera Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jetrea$1,500
- Clarus 700$206
- Non-Covered Product$140
- VABYSMO$131
- EYLEA$111
How this compares
$4,649 in reported general payments places this provider in the 55th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 24 | $7,780 |
| Prednisolone Acetate | 204 | $6,868 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $4,865 |
| Ketorolac Tromethamine | 179 | $3,165 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $2,411 |
| Brimonidine Tartrate | 66 | $1,821 |
| Latanoprost | 185 | $1,675 |
| Dorzolamide Hcl | 40 | $684 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 69 | $675 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $493 |
| ErythromycinErythromycin Base | 35 | $359 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $232 |
| Ofloxacin | 20 | $203 |
| Timolol Maleate | 42 | $174 |
| Prednisone | 19 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $622 | $2,41112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 70 retina specialist providers in Illinois.
Other retina specialist in Bloomington
- Mathew MaccumberHarvey$219K
- Rahul KomatiChicago$143K
- Kourous RezaeiHarvey$126K
- Kirk PackoHarvey$86K
- David OrthHarvey$70K
- Veena RaijiChicago$69K
- John PollackJoliet$68K
- Timothy FloodHarvey$57K
- Brian LarsenLombard$38K
- Serge DebustrosHarvey$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.